The anti-psychotic drug Risperdal (risperidone) has been associated with severe side effects, including gynecomastia (male breast growth), severe weight gain, and type-2 diabetes.
Johnson & Johnson Settles Risperdal Class Action Lawsuits
Johnson & Johnson (J&J) has lost four consecutive Risperdal class action lawsuits with Attorneys General in the following states: Texas ($158 million), South Carolina ($327 million), Arkansas ($1.2 billion, under appeal), and Louisiana ($257.7 million).
Prosecutors accused J&J of defrauding taxpayer-funded healthcare systems by using illegal marketing tactics to promote Risperdal over cheaper, equally-effective drugs. These tactics included making payments to physicians employed in state government, using questionable studies, and paying kickbacks to doctors who prescribed Risperdal.
Johnson & Johnson Pays $2.2 Billion in Risperdal Class Action Settlement
November 2013 — Johnson & Johnson (J&J) will pay $2.2 billion in a settlement to the U.S. Department of Justice (DOJ). Attorneys filed civil and criminal lawsuits after uncovering evidence that J&J illegally marketed Risperdal “off-label” in children, ignored FDA warnings and studies linking Risperdal to gynecomastia (male breast growth) in children, and paid kickbacks to doctors. Click here to read more.
Risperdal Lawsuit Settlements
Johnson & Johnson (J&J) has already settled several individual Risperdal lawsuits with young men who developed gynecomastia. The first settlement was given to a 21 year-old man who developed breasts after taking Risperdal when he was 9 years old. In October 2012, J&J agreed to four more settlements before trials could begin.